Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01108848 · ClinicalTrials.gov registry record
Patient Registry Study of Berinert® in Normal Clinical Practice
A clinical trial, sponsored by CSL Behring.
- Completed
- Registry status
- 318
- Enrollment target
NCT01108848: Completed study, sponsored by CSL Behring.
NCT01108848 is a clinical trial that has completed, run by CSL Behring. The registered enrollment target is 318 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01108848 has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- 318 participants
- Enrollment target
Study Summary
The objective of this patient registry is to collect data on the safety of Berinert® in normal clinical practice in the United States. The patient registry will be maintained for a period of at least 3 years. The duration of individual patient participation will vary and is determined by the frequency of hereditary angioedema (HAE) attacks and the patient's need for Berinert® treatment.
Interventions
- BIOLOGICAL Berinert® (C1 Esterase Inhibitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 318 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-04 |
What the finished NCT01108848 record still lists
NCT01108848 is an observational study that tracks outcomes without assigning an intervention. The registered 318 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Berinert® (C1 Esterase Inhibitor) is the first listed.
NCT01108848 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01108848 about?
NCT01108848 is a clinical study titled "Patient Registry Study of Berinert® in Normal Clinical Practice". The objective of this patient registry is to collect data on the safety of Berinert® in normal clinical practice in the United States. The patient registry will be maintained for a period of at least 3 years. The duration of individual patient participation will vary and is determined by the frequen...
What is the current status of trial NCT01108848?
This trial is currently completed. The enrollment target is 318 participants. The study started on 2010-04. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01108848?
The interventions under investigation include: Berinert® (C1 Esterase Inhibitor) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01108848?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05488340 · 318 participants · Phase 2
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
- NCT05675735 · 318 participants · NA
Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder
- NCT05895786 · 318 participants · Phase 3
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- NCT06051617 · 318 participants · Phase 3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia